| Factor Information | |
|---|---|
| Data ID | 612 |
| Factor | SPO2 |
| Description | N/A |
| Biomarker | NA |
| Classification | E11 (physiological factor - physical sign) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | CHD patients with PAH |
| p Value | 0.002 |
| Conclusion | SOP2 was increased significantly in post-treatment group. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 472 |
| CHD Type | isolated CHD |
| CHD Subtype | VSD with PAH/ASD with PAH/PDA with PAH |
| Reference | |
|---|---|
| PMID | 29177254 |
| Year | 2017 |
| Title | Semi-quantitative assessment of pulmonary arterial hypertension associated with congenital heart disease through myocardial perfusion imaging |
| Sample | ||
|---|---|---|
| Population | adolescent, adult | |
| Source | data | |
| Region | China, Wuhan | |
| Method | T-test | |
| Race | Asian | |
| Disease History | N/A | |
| Treatment History | medicine and operation intervention | |
| Group | pre-treatment(Treatment) | post-treatment(Control) |
| Number | 24 | 24 |
| Age | 25±6.9 years | 25±6.9 years |
| Gender (Male: Female) | 10:14:00.000 | 10:14:00.000 |
| Marker Level | 94.10±5.37% | 95.87±4.04% |
